person · Reporting owner

Giordano Douglas E.

Disclosed activity across 5 companies

Tapewire entity: 36317
SEC CIK: 0001431552

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ICU MEDICAL INC/DEICUI · Entity 2385	Director	February 03, 2017	February 08, 2017
Kardigan, Inc.KARD · Entity 4569	Director	June 17, 2026	June 22, 2026
Panacea Acquisition Corp. IIPANA · Entity 114006	Director	April 06, 2021	April 07, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ICU MEDICAL INC/DE

Report date February 03, 2017 · Filed February 08, 2017

This filing explicitly reported no securities owned.

Kardigan, Inc.

Report date June 17, 2026 · Filed June 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	20,706	Reported balance After 2026-06-17 transaction · row 1 1 source row Row 1 · 2026-06-17 · Grant · Acquired 20,706 · Balance 20,706 F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date.

Panacea Acquisition Corp. II

Report date April 06, 2021 · Filed April 07, 2021

This filing explicitly reported no securities owned.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Cerevel Therapeutics Holdings, Inc.

Report date August 01, 2024 · Filed August 05, 2024

Section 16 reporting ended · disclosed 2024-08-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2024-08-01 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2024-08-01 · Disposition to issuer · Disposed 3,282 · Balance 10,461 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. Row 2 · 2024-08-01 · Disposition to issuer · Disposed 10,461 · Balance 0 F2: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	0	Reported balance After 2024-08-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-08-01 · Disposition to issuer · Disposed 95,242 · Balance 0 F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest.

F2: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.

F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.

Viatris Inc

Report date November 16, 2020 · Filed November 16, 2020

Section 16 reporting ended · disclosed 2020-11-16. Current position is not established by this disclosure.

No balance rows disclosed in this filing.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 17, 2026 Filed Jun 22, 2026 23:15 UTC	Kardigan, Inc. KARD · Entity 4569	GrantCommon Stock	20,706	$0.00	$0.00	Disclosure SEC source: 0001193125-26-277911 · ownership.xml · nonDerivative · entry 1 Giordano Douglas E. · CIK 0001431552 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,706 F1 · kind: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date. Read SEC document
August 01, 2024 Filed Aug 5, 2024 16:36 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	Disposition to issuerStock Option (Right to Buy) · Derivative	95,242	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-090853 · ownership.xml · derivative · entry 3 Giordano Douglas E. · CIK 0001431552 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 95,242 shares Expires not disclosed F3 · derivative.exercise_price: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F3 · price: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F3 · derivative.exercise_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F3 · derivative.expiration_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. Read SEC document
August 01, 2024 Filed Aug 5, 2024 16:36 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	Disposition to issuerCommon Stock	10,461	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-090853 · ownership.xml · nonDerivative · entry 2 Giordano Douglas E. · CIK 0001431552 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · shares: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. F2 · price: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. Read SEC document
August 01, 2024 Filed Aug 5, 2024 16:36 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	Disposition to issuerCommon Stock	3,282	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-090853 · ownership.xml · nonDerivative · entry 1 Giordano Douglas E. · CIK 0001431552 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,461 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. Read SEC document
June 05, 2024 Filed Jun 7, 2024 16:30 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	GrantCommon Stock	10,461	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-070724 · ownership.xml · nonDerivative · entry 1 Giordano Douglas E. · CIK 0001431552 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,743 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the 2025 annual meeting of stockholders of the Company. F1 · price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the 2025 annual meeting of stockholders of the Company. Read SEC document
June 07, 2023 Filed Jun 9, 2023 16:15 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	GrantStock Option (Right to Buy) · Derivative	13,780	$0.00 Strike: $32.60	$0.00	Disclosure SEC source: 0000899243-23-015181 · doc4.xml · derivative · entry 2 Giordano Douglas E. · CIK 0001431552 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,780 Underlying: Common Stock · 13,780 shares Expires 2033-06-07 F2 · derivative.exercise_date: 100% of the shares subject to this option shall vest and become exercisable on the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date. Read SEC document
June 07, 2023 Filed Jun 9, 2023 16:15 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	GrantCommon Stock	3,282	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-23-015181 · doc4.xml · nonDerivative · entry 1 Giordano Douglas E. · CIK 0001431552 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,282 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date. F1 · price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date. Read SEC document
June 14, 2022 Filed Jun 16, 2022 16:46 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	GrantStock Option (Right to Buy) · Derivative	23,459	$0.00 Strike: $24.35	$0.00	Disclosure SEC source: 0000899243-22-022833 · doc4.xml · derivative · entry 1 Giordano Douglas E. · CIK 0001431552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,459 Underlying: Common Stock · 23,459 shares Expires 2032-06-14 F1 · derivative.exercise_date: 100% of the shares subject to this option shall vest and become exercisable on the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date. Read SEC document
June 10, 2021 Filed Jun 14, 2021 20:04 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	GrantStock Option (Right to Buy) · Derivative	58,003	$0.00 Strike: $13.93	$0.00	Disclosure SEC source: 0000899243-21-023716 · doc4.xml · derivative · entry 1 Giordano Douglas E. · CIK 0001431552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,003 Underlying: Common Stock · 58,003 shares Expires 2031-06-10 F1 · derivative.exercise_date: 100% of the shares subject to this option shall vest and become exercisable on the earlier of: (i) the one year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.